Skip to main content
Premium Trial:

Request an Annual Quote

MDxHealth Revenues Up in First Four Months of 2017

NEW YORK (GenomeWeb) – Belgian diagnostics company MDxHealth announced today a 128 percent increase in revenues for the first four months of 2017.

For the four-month period ended April 30, MDxHealth's revenues climbed to $19.4 million from $8.5 million year over year. Contributing to the increase was a 25 percent rise in the number of patients tested with the company's ConfirmMDx and recently launched SelectMDx prostate cancer assays to 8,000 from 6,400.

MDxHealth also said that it had cash and cash equivalents totaling $35.1 million as of April 30, which includes $15 million received from Exact Sciences for the rights to its colorectal cancer-related patents.

Looking ahead, MDxHealth said that it is maintaining its full-year 2017 guidance of between 55 percent and 75 percent growth on product and service income, and that it anticipates increasing private payor adoption and securing favorable reimbursement rates for ConfirmMDx and SelectMDx in the US. The firm added that it continues to expect to launch its AssureMDx bladder cancer test — its second liquid biopsy test after SelectMDx — in 2017.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.